413 related articles for article (PubMed ID: 10882607)
21. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
22. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
23. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.
Brime B; Molero G; Frutos P; Frutos G
Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515
[TBL] [Abstract][Full Text] [Related]
24. [Anti-infectious effect of sustained antravitreal amphotericin B drug delivery system on experimental rabbit fungal endophthalmitis of Candida albicans].
Chen N; Yang YT; Dong XG; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2006 May; 42(5):420-5. PubMed ID: 16762236
[TBL] [Abstract][Full Text] [Related]
25. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
26. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
27. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
28. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
30. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
31. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
[TBL] [Abstract][Full Text] [Related]
32. Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603
[TBL] [Abstract][Full Text] [Related]
33. A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection.
Shao K; Wu J; Chen Z; Huang S; Li J; Ye L; Lou J; Zhu L; Jiang C
Biomaterials; 2012 Oct; 33(28):6898-907. PubMed ID: 22789719
[TBL] [Abstract][Full Text] [Related]
34. Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model.
Takemoto K; Nakayama T; Kanazawa K; Ueda Y
Pharmacology; 2012; 90(3-4):133-45. PubMed ID: 22847175
[TBL] [Abstract][Full Text] [Related]
35. In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments.
Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
J Antimicrob Chemother; 2003 Sep; 52(3):412-8. PubMed ID: 12917237
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
[TBL] [Abstract][Full Text] [Related]
37. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
